Ad Header



The Pulse of the Pharmaceutical Industry

Merck KGaA, Pfizer’s immuno-drug shown to alleviate kidney cancer

Written by: | | Dated: Tuesday, September 11th, 2018


FRANKFURT (Reuters) – Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer’s Inlyta drug in a late-stage study.

The drug combination led to longer progression-free survival in patients with advanced renal cell carcinoma (RCC) when compared with a control group on older Pfizer drug Sutent, the German drugmaker said in a statement on Tuesday.

The trial will continue to show whether Bavencio plus Inlyta also prolongs patients’ lives.

While the company said the benefit was statistically significant, they did not specify the duration of progression-free survival. A detailed analysis would be submitted for presentation at a medical congress, it added.


Reporting by Ludwig Burger; Editing by Maria Sheahan


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom